Preclinical Safety, Efficacy Testing, and Technology Transfer of Novel Compounds for Drugs
The following organizations have been working together: Center for Development of New Drugs (Orchemed), Institute of Physiologically Active Compounds (Chernogolovka), Medivation (San Francisco), University of California at Santa Cruz, and Tufts University. They have formed one of the few preclinical testing organizations with modern facilities in Russia. They have spawned a consortium of 13 Russian universities and their U.S. partners. They are now promoting promising technologies and support of the Russian pharmaceutical industry. This joint effort has supported presentation of Russian pharmaceutical products in compliance with international quality standards, thereby facilitating their routes to international markets.
SOURCE: ISTC Annual Report 2011, p. 15, 2012.
Haemophilus Influenza Research and Vaccination Program
In 2010, the Vishnevskaya-Rostropovich Foundation completed studies that showed a significant burden of Hib meningitis in children, in both western Russia and the Far East. The foundation supported vaccination programs in Yaroslavl, the Murmansk regions, and Vladivostok. Over 70,000 children were vaccinated. As a result, the Hib vaccine has been added to the national vaccination calendar, and its administration is now financed by the Ministry of Health and Social Services.
SOURCE: Vishnevskaya-Rostropovich Foundation, March 2012.
TIME FOR BALANCING THE LEDGER
Most examples that are cited above and noted in the appendixes of this report focus on activities in Russia, with the U.S. side usually providing most of the financial resources for covering the direct costs of implementing joint projects. This approach can be traced back to the economic crisis of the 1990s and the pat-